CYTR CytRx Corporation

+0.1045  (21%)
Previous Close 0.50
Open 0.51
Price To book 4.10
Market Cap 92.57M
Shares 152,054,000
Volume 17,730,243
Short Ratio 7.79
Av. Daily Volume 4,840,680

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 poster at ASCO June 4, 2017. Abstract 11051.
Advanced sarcomas - cancer
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017. Oral presentation ASCO June 3, 2017. Abstract 11000.
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 2 completed.
Cancer - AIDS-related Kaposi’s sarcoma
Phase 2 trial completed.
Cancer - unresectable glioblastoma
Phase 2b data due 2Q 2017.
Relapsed/refractory small cell lung cancer

Latest News

  1. The Most Notable Abstracts Released Ahead Of ASCO 2017
  2. Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx
  3. CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting
  4. CytRx reports 1Q loss
  5. CytRx Reports First Quarter 2017 Financial Results
  6. CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock
  7. CytRx Corporation Announces Proposed Public Offering of Common Stock
  8. Penny Stocks to Watch for May 2017
  9. CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)
  10. CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
  11. ETFs with exposure to CytRx Corp. : April 20, 2017
  12. Blog Coverage CytRx Announces FDA's Approval for New Drug Application
  13. CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
  14. For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1
  15. CytRx Corp. :CYTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  16. CytRx Reports 2016 Financial Results
  17. The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
  18. CytRx to Present at the 29th Annual ROTH Conference
  19. CytRx to Present at the 19th Annual BIO CEO & Investor Conference